Jorge Luis Sandoval-ramírez - Infectious Diseases

Author Information

Jorge Luis Sandoval-Ramírez is associated with the Infectious Diseases Department at the Hospital de Infectología, "La Raza" National Medical Center, IMSS, located in Mexico City, Mexico. His work primarily focuses on infectious diseases, with a special emphasis on HIV research. His contributions have been significant in understanding the genetic and clinical aspects of infectious diseases in the Mexican population.

Research Contributions

Jorge Luis Sandoval-Ramírez has made notable contributions to the field of infectious diseases, particularly concerning HIV/AIDS. His research includes studies on the genetic variants contributing to hypertriglyceridemia in HIV patients receiving antiretroviral therapy, effectiveness of HIV treatment regimens, and risk factors associated with mortality in influenza A/H1N1 infections. He has explored various aspects of HIV treatment including etravirine-based and darunavir-based therapies, and the prevalence of antibodies against Treponema pallidum among HIV-positive patients.

Aliases

Jorge Luis Sandoval-Ramírez is also known by several aliases, including J L Sandoval-ramirez, Jorge Luis Sandoval-ramirez, Jorge Sandoval-Ramírez, and Jorge Luis Sandoval-Ramírez. These variations may appear in different publications or databases.

Publication and Citation Metrics

Metric	Value
Total Papers	11
Total Citations	59
H-index	4

Publications:

Contribution of APOA5, APOC3, CETP, ABCA1 and SIK3 genetic variants to hypertriglyceridemia development in Mexican HIV-patients receiving antiretroviral therapy

DOI: 10.1097/FPC.0000000000000458

Year: 2021

Effectiveness of etravirine-based therapy for treatment-experienced HIV-infected patients.

DOI: 10.3855/jidc.7512

Year: 2016

Risk factors associated with mortality in patients infected with influenza A/H1N1 in Mexico

DOI: 10.1186/s13104-015-1349-8

Year: 2015

Anal intraepithelial neoplasia among HIV-positive men who have sex with men.

DOI: 10.1071/SH15085

Year: 2015

Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C.

DOI: 10.3855/jidc.5284

Year: 2015

Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients

DOI: 10.1186/s12981-015-0072-9

Year: 2015

Prevalence of antibodies against Treponema pallidum among HIV-positive patients in a tertiary care hospital in Mexico

DOI: 10.1177/0956462414530888

Year: 2015

Intensification of treatment with pegylated interferon alfa in patients coinfected with HIV and HBV genotype H or G being treated with a tenofovir/emtricitabine-containing regimen.

DOI:

Year: 2014

Intensification of treatment with pegylated interferon alfa in patients coinfected with HIV and HBV genotype H or G being treated with a tenofovir/emtricitabine-containing regimen.

DOI:

Year: 2014

Effectiveness of enfuvirtide in a cohort of highly antiretroviral-experienced HIV-1-infected patients in Mexico

DOI: 10.1186/s12981-014-0040-9

Year: 2014

Why Are Masks Important in Infectious Disease Prevention?

How is Dengue Hemorrhagic Fever Diagnosed?

What Should You Do if You Suspect Contamination?

What is the Role of Genomics in Tracking Disease Outbreaks?

What Pathogens Can Be Detected in Stool Samples?

Are There Any Concerns About Drug Resistance?

What Role Does Community Engagement Play?

When are Imaging Studies Recommended?

When is a Biopsy Indicated?

When is Ultrasound Used?

Partnered Content Networks

Relevant Topics